Trial Profile
Revlimid / dexamethasone (RevDex) as induction therapy prior to transplantation of peripheral blood progenitor cells for the treatment of patients with newly diagnosed multiple myeloma, Revlimid monotherapy followed by maintenance therapy. Comparison of two strategies for mobilization of peripheral blood progenitor cells [Revlimid/dexametasona (RevDex) como tratamiento de induccion previo al trasplante de celulas progenitoras de sangre periferica para el tratamiento de pacientes con mieloma multiple de nuevo diagnostico, seguido de Revlimid en monoterapia como tratamiento de mantenimiento. Comparacion de dos estrategias de movilizacion de celulas progenitoras de sangre periferica]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2016
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Mar 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 25 Aug 2011 New trial record